IGF2BP1 and cancer: Not only did higher expression of IGF2BP1 correlate with poorer outcomes in EAC and LUAD (Fig 6C and 6D), but the same trend was seen when we pooled several other ADCs from the TCGA Pan-Cancer dataset (including cancers of the breast, prostate, endocervix, endometrium, ovary, pancreas, stomach, kidney, colon, rectum, and thyroid) (Fig 6E).